Patent: 8,568,766
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,568,766
Title: | Peptides and peptide mimetics to treat pathologies associated with eye disease |
Abstract: | This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection. |
Inventor(s): | Anantharamaiah; Gattadahalli M. (Birmingham, AL), Fogelman; Alan M. (Beverly Hills, CA), Navab; Mohamad (Los Angeles, CA), Rudolf; Martin (Lubeck, DE) |
Assignee: | |
Application Number: | 12/027,728 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,568,766 |
Patent Claims: | see list of patent claims |
Details for Patent 8,568,766
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2020-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2020-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2020-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2020-08-24 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2020-08-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |